MSCRF Clinical Program supports organizations conducting human stem cell-based clinical research in Maryland to advance therapies for human diseases, injuries, and conditions and address unmet medical needs.
Funder: Maryland Technology Development Corporation (TEDCO)
Due Dates: January 20, 2027, 5:00 p.m. EST (Application) | Week of April 4, 2027 (In-person review) | May 2027 (Award announcement)
Funding Amounts: Up to $1,000,000 in direct costs over a maximum of two years; 1:1 non-state match required
Summary: Supports human stem cell-based clinical research conducted in Maryland to advance therapies for human diseases, injuries, and conditions.
Key Information: Clinical trials must have an FDA-cleared IND or IDE before application submission.
The Maryland Stem Cell Research Fund (MSCRF), administered by TEDCO, supports clinical research translating human stem cell discoveries into medical therapies. Projects may involve human stem cells, derivatives such as extracellular vesicles and secretome, or technologies that enable or support human stem cells. The program seeks advances in prevention, diagnosis, treatment, and cure of human diseases, injuries, and conditions.
The Clinical Program funds organizations conducting research in Maryland, including organizations headquartered elsewhere. It encourages collaboration across academic schools, departments, and institutions and between public and private sectors. Priorities include advancing regenerative medicine, addressing unmet medical needs, improving on existing therapies or devices, and significantly influencing clinical treatment or medical practice.